Ehab Atallah
Medical College of Wisconsin · Medical College of Wisconsin adn Froedtert Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Ehab Atallah as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:15 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05628623 · Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia (AML) Following Initial TreatmentEastern Cooperative Oncology Group · not yet recruiting · Leukemia, Myeloid, Acute · study chair
- Ph1NCT05038644 · XmAb18968 (CD3-CD38) in Relapsed or Refractory Acute Leukemia and T Cell Lymphoblastic LeukemiaEhab L Atallah · terminated · Acute Myeloid Leukemia, T Cell Acute Lymphoblastic Leukemia, T Cell Lymphoblastic Lymphoma · principal investigator
- Ph2NCT04838041 · Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI DiscontinuationMedical College of Wisconsin · recruiting · Chronic Phase Chronic Myelogenous Leukemia · principal investigator
- Ph1NCT04172844 · Pevonedistat, Azacitidine (or Decitabine), and Venetoclax for the Treatment of Patients With Acute Myelogenous LeukemiaMedical College of Wisconsin · terminated · Acute Myelogenous Leukemia · principal investigator
- Ph2NCT03151304 · A Safety and Efficacy Study of Pracinostat and Azacitidine in Patients With High Risk Myelodysplastic SyndromesHelsinn Healthcare SA · terminated · Myelodysplastic Syndromes · study chair
- Ph2NCT03150004 · Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)Medical College of Wisconsin · terminated · Acute Myeloid Leukemia, Myelodysplastic Syndrome · principal investigator
- Ph2NCT03140280 · Hypomethylating Properties of Freeze-dried Black Raspberries (BRB) in Patients With Myelodysplastic Syndrome or Myelodysplastic Syndrome/Myeloproliferative Neoplasm (MDS/MPN)Ehab L Atallah · completed · Myelodysplastic Syndromes · principal investigator
- Ph1NCT02578511 · Standard Maintenance POMP/D Plus Ixazomib Maintenance Therapy in Adult Patients With Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma or Mixed Phenotype Acute Leukemia in Complete Remission (CR)Ehab L Atallah · withdrawn · Acute Lymphoblastic Leukemia in Complete Remission, Lymphoblastic Lymphoma in Complete Remission, Mixed Phenotype Acute Leukemia in Complete Remission · principal investigator
- Ph2NCT02269267 · The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)Medical College of Wisconsin · completed · Leukemia, Myeloid, Chronic · principal investigator
- Ph1NCT00827138 · Study Safety and Preliminary Efficacy of DCC-2036 in Patients With Leukemias (Ph+ CML With T315I Mutation)Deciphera Pharmaceuticals, LLC · completed · Chronic Myeloid Leukemia · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:15 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Stopping Tyrosine Kinase Inhibitors in CML Patients (Stop-TKIs)R01CA184798 · NCI · MEDICAL COLLEGE OF WISCONSIN · fiscal years 2014 to 2019 · $361,156 awarded in 2019Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name in chronic myeloid leukemia, ranked by citations from NIH iCite, fetched 2026-11-12 11:15 UTC. The ranking covers the 200 most relevant of 2 PubMed records, and a shared surname and initials can bring in a namesake. All 2 on PubMed
- Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial.JAMA Oncol · 202194 citationsRCR 5.8
- Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia.Haematologica · 202212 citationsRCR 1.0